Abbrea Capital LLC Has $354,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Abbrea Capital LLC grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 55.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,560 shares of the company’s stock after buying an additional 1,275 shares during the quarter. Abbrea Capital LLC’s holdings in Moderna were worth $354,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its position in shares of Moderna by 77.3% in the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Invesco Ltd. lifted its position in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after purchasing an additional 476,201 shares in the last quarter. Bamco Inc. NY lifted its position in shares of Moderna by 4,863.6% in the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after purchasing an additional 418,269 shares in the last quarter. Finally, abrdn plc lifted its position in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of a number of research reports. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. HSBC reissued a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Canaccord Genuity Group boosted their price objective on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $126.49.

Moderna Stock Performance

Shares of MRNA traded down $2.67 during trading hours on Thursday, hitting $106.18. The company had a trading volume of 2,793,180 shares, compared to its average volume of 4,100,587. The firm has a market cap of $40.65 billion, a price-to-earnings ratio of -8.56 and a beta of 1.62. The business has a fifty day moving average of $101.85 and a 200-day moving average of $93.64. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company’s revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.61 earnings per share. Equities analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the transaction, the director now directly owns 2,056,931 shares in the company, valued at $212,645,526.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the transaction, the director now directly owns 2,056,931 shares in the company, valued at $212,645,526.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,954 shares of company stock worth $11,533,976. Corporate insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.